TY - JOUR
T1 - Protease inhibitors do not affect antibody responses to pneumococcal vaccination
AU - De La Rosa, Indhira
AU - Munjal, Iona M.
AU - Rodriguez-Barradas, Maria
AU - Yu, Xiaoying
AU - Pirofski, Liise Anne
AU - Mendoza, Daniel
N1 - Funding Information:
This work, including the efforts of Liise-anne Pirofski, was funded by HHS | National Institutes of Health (NIH) (R01AG045044). This work, including the efforts of Liise-anne Pirofski, was funded by HHS | National Institutes of Health (NIH) (R56AI104234). This work, including the efforts of Daniel Mendoza, was funded by American Association of Immunologists (AAI).
Publisher Copyright:
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
PY - 2016/6
Y1 - 2016/6
N2 - HIV+ subjects on optimal antiretroviral therapy have persistently impaired antibody responses to pneumococcal vaccination. We explored the possibility that this effect may be due to HIV protease inhibitors (PIs). We found that in humans and mice, PIs do not affect antibody production in response to pneumococcal vaccination.
AB - HIV+ subjects on optimal antiretroviral therapy have persistently impaired antibody responses to pneumococcal vaccination. We explored the possibility that this effect may be due to HIV protease inhibitors (PIs). We found that in humans and mice, PIs do not affect antibody production in response to pneumococcal vaccination.
UR - http://www.scopus.com/inward/record.url?scp=84973473369&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84973473369&partnerID=8YFLogxK
U2 - 10.1128/CVI.00026-16
DO - 10.1128/CVI.00026-16
M3 - Article
AN - SCOPUS:84973473369
SN - 1556-6811
VL - 23
SP - 524
EP - 529
JO - Clinical and Diagnostic Laboratory Immunology
JF - Clinical and Diagnostic Laboratory Immunology
IS - 6
ER -
